60 articles
Adrian M. Di Bisceglie
Adrian M. Di Bisceglie is a South African-born hepatologist known for research on viral hepatitis, who led the liver diseases section at the NIH and joined Saint Louis University in 1994.
Anna S. Lok
Anna Suk-Fong Lok is a hepatologist at the University of Michigan who led the first interferon-free cure of hepatitis C and authored the first WHO hepatitis B guideline.
Barbara Rehermann
Barbara Rehermann is a German-trained physician-scientist who leads the Immunology Section of the Liver Diseases Branch at NIH, studying immune responses to hepatitis B and C.
Edward Gane
Edward Gane, formally Edward John Gane, is a New Zealand hepatologist at Auckland City Hospital who led trials of the first oral, interferon-free cure for hepatitis C.
Eric Lawitz
Eric Lawitz (Eric J. Lawitz) is an American hepatologist and clinical trialist known for leading phase 3 sofosbuvir trials that replaced interferon-based hepatitis C therapy with all-oral antiviral regimens.
Fabien Zoulim
Fabien Zoulim is a French hepatologist and virologist known for hepatitis B cure research, who heads hepatology at the Hospices Civils de Lyon and co-founded ICE-HBV.
Fasiha Kanwal
Fasiha Kanwal is a physician-scientist and tenured professor of medicine at Baylor College of Medicine in Houston, known for VA cohort research on liver cancer risk in hepatitis C.
Fred Poordad
Fred Poordad is an American hepatologist at UT Health San Antonio and the Texas Liver Institute who led pivotal hepatitis C trials, including the 2011 SPRINT-2 boceprevir study.
Gary L. Davis
Gary L. Davis is an American hepatologist known for the 1998 interferon and ribavirin trial for chronic hepatitis C, who led liver units at Florida and Baylor.
Geoffrey Dusheiko
Geoffrey Dusheiko is a hepatologist and Emeritus Professor of Medicine at University College London, known for research on viral hepatitis B, C, and D and antiviral therapy.
Gregory J. Dore
Gregory J. Dore, known as Greg Dore, is an Australian hepatologist at the Kirby Institute and St Vincent's Hospital, Sydney, known for hepatitis C research and elimination policy.
Harry L.A. Janssen
Harry L.A. Janssen (Harry Janssen) is a Dutch hepatologist, Professor and Chair of Gastroenterology and Hepatology at Erasmus MC in Rotterdam, known for the 2013 miravirsen hepatitis C trial.
Heiner Wedemeyer
Heiner Wedemeyer, born 1967 and recorded as Hans-Heinrich Wedemeyer, is a German hepatologist and director of gastroenterology at Hannover Medical School known for hepatitis D research and bulevirtide's development.
Howard C. Thomas
Howard C. Thomas, or Howard Christopher Thomas, is a British hepatologist born in 1945 who defined the phases of chronic hepatitis B and led the first European interferon trials.
Ira M. Jacobson
Ira M. Jacobson, also known as Ira Jacobson, is an American hepatologist who leads pivotal hepatitis B and C clinical trials as director of hepatology at NYU Langone Health.
Jack R. Wands
Jack R. Wands, also known as Jack Wands, was an American hepatologist who studied viral hepatitis and liver cancer for over fifty years, leading Brown's gastroenterology division from 1999 to 2023.
Jay H. Hoofnagle
Jay H. Hoofnagle is an American hepatologist who directed NIH's Liver Disease Research Branch and established interferon as the first treatment for chronic viral hepatitis.
Jean–Michel Pawlotsky
Jean-Michel Pawlotsky, born in 1961, is a French physician-scientist in hepatology and virology, professor at Université Paris-Est Créteil and director of virology at Hôpital Henri Mondor in Créteil.
Jeffrey S. Glenn
Jeffrey S. Glenn is an American physician-scientist at Stanford University who studies viral hepatitis and broad-spectrum antivirals, directing the Center for Hepatitis and Liver Tissue Engineering.
Jenny Heathcote
Jenny Heathcote is a British-born Canadian hepatologist known for her 1970s studies of hepatitis B transmission and for autoimmune liver disease research at the University of Toronto.
Jens Bukh
Jens Bukh (born 1960) is a Danish virologist who first published that hepatitis C virus has six major genotypes and directs the Copenhagen Hepatitis C Program.
John B. Wong
John B. Wong is an American physician-scientist at Tufts Medical Center in Boston, known for cost-effectiveness modeling of hepatitis B and service on the US Preventive Services Task Force.
John G. McHutchison
John G. McHutchison is an Australian-born hepatologist and clinical trialist whose trials transformed hepatitis C into a curable disease; he has led Tune Therapeutics as CEO since March 2025.
Jordan J. Feld
Jordan J. Feld is a Canadian hepatologist, Professor of Medicine at the University of Toronto, and Director of the Toronto Centre for Liver Disease, known for leading trials that cure hepatitis C.
Jules L. Dienstag
Jules L. Dienstag is an American hepatologist, a physician at Massachusetts General Hospital since 1976 and Harvard professor, known for lamivudine trials and a widely cited 2008 hepatitis B review.
Kazuaki Chayama
Kazuaki Chayama (茶山 一彰) is a Japanese hepatologist, long a professor at Hiroshima University, known for work on hepatitis B drug resistance, hepatitis C therapy, and liver cancer genetics.
Kazuhiko Koike
Kazuhiko Koike (小池 和彦) is a Japanese hepatologist and gastroenterologist who was a professor at the University of Tokyo until 2021, known for his hepatitis C research.
Kenneth E. Sherman
Kenneth E. Sherman is an American hepatologist and Gould Professor emeritus at the University of Cincinnati, first author of the 2011 ILLUMINATE telaprevir trial for hepatitis C.
Kris V. Kowdley
Kris V. Kowdley, also published as Kris Kowdley, is an American hepatologist who designs and leads international clinical trials of new treatments for hepatitis C and other liver diseases.
Laurent Castéra
Laurent Castéra is a French hepatologist, professor of hepatology at Université Paris Cité and Hôpital Beaujon in Clichy, who led EASL and pioneered noninvasive liver fibrosis testing.